Research Progress in Hepatotoxicity and Prevention and Treatment of Arsenic Trioxide

doi:10.19803/j.1672-8629.2020.03.11

Abstract

Abstract: Arsenic trioxide is used in the treatment of acute promyelocytic leukemia and other malignant tumors, to good effect. However, in recent years, arsenic trioxide has been found to have hepatotoxic effect, which limits its clinical application. There was the finding that the hepatotoxicity of arsenic trioxide was related to the increase of oxidative stress and the induction of apoptosis. In this paper, the mechanism of hepatotoxicity of arsenic trioxide and its prevention and treatment were reviewed.

Key words: arsenic trioxide, acute promyelocytic leukemia, hepatotoxicity, oxidative stress, apoptosis

CLC Number:

R595.2

SUN Jiafu, SUN Xiao, SUN Guibo, SUN Xiaobo, NAN Fengwei, LUO Yun, GAO Ye, WANG Shan. Research Progress in Hepatotoxicity and Prevention and Treatment of Arsenic Trioxide[J]. Chinese Journal of Pharmacovigilance, 2020, 17(3): 177-183.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.03.11

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I3/177

References

[1] Cui YH, Liang HJ, Zhang QQ, et al.Radiosensitivity enhanc- ement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line[J]. Asian Pacific Journal of Cancer Prevention Apjcp, 2012, 13(4):1693-1697.
[2] Wang X, Li D, Ghali L, et al.Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal Nanotechnology[J]. Nanoscale Research Letters, 2016, 11(1):94.
[3] Chang KJ, Yang MH, Zheng JC, et al.Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer[J]. Am J Transl Res, 2016, 8(2):1133-1143.
[4] Acosta D, Sorensen EM, Anuforo DC, et al.An in vitro approach to the study of target organ toxicity of drugs and chemicals[J]. Vitro Cellular & Developmental Biology Journal of the Tissue Culture Association, 1985, 21(9):495-504.
[5] Sanz MA, Lo-Coco F.Arsenic Trioxide: Its Use in the Treatment of Acute Promyelocytic Leukemia[J]. American Journal of Cancer, 2006, 5(5):183-191.
[6] Lazo G, Kantarjian H, Estey E, et al.Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience[J]. Cancer, 2010, 97(9):2218-2224.
[7] Mathews V, Desire S, George B, et al.Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity[J]. Leukemia, 2006, 20(5):881-883.
[8] Mathews V, George B, Chendamarai E, et al.Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data[J]. Journal of Clinical Oncology, 2010, 28(24):3866-3871.
[9] Mathews VV, Binu P, Paul MS, et al.Hepatoprotective efficacy of curcumin against arsenic trioxide toxicity[J]. Asian Pacific Journal of Tropical Biomedicine, 2012, 2(2): S706-S711.
[10] Hao L, Zhao J, Wang X, et al.Hepatotoxicity From Arsenic Trioxide for Pediatric Acute Promyelocytic Leukemia[J]. Journal of Pediatric Hematology/Oncology, 2013, 35(2):1.
[11] Lococo F, Avvisati G, Vignetti M, et al.Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia[J]. New England Journal of Medicine, 2013, 369(2):111-121.
[12] Burnett AK, Russell NH, Hills RK, et al.Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial[J]. Lancet Oncology, 2015, 16(13):1295-1305.
[13] 甘戈, 孙骏, 王佳域,等. 27例三氧化二砷严重不良反应病例报告分析[J]. 中国药物警戒, 2008, 5(5):286-290.
[14] 胡亚男, 赵巍, 陈承志,等. 亚砷酸钠和三氧化二砷对人正常肝细胞增殖与凋亡效应的影响[J]. 卫生研究, 2014, 43(2): 203-209.
[15] Ray A, Roy S, Agarwal S, et al.As2O3 toxicity in rat hepatocytes: manifestation of caspase-mediated apoptosis[J]. Toxicol Ind Health, 2008,24(10): 643-653.
[16] Wang H, Chen XY, Wang BS, et al.The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis[J]. Leukemia Research, 2011, 35(9):1170-1177.
[17] Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al.Treat- ment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy[J]. Annals of Oncology, 2006, 17(1):131.
[18] Ramachandran A, Jaeschke H.Oxidative Stress and Acute Hepatic Injury[J]. Curr Opin Toxicol, 2018(7): 17-21.
[19] Ghosh A, Mandal AK, Sarkar S, et al.Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic- induced oxidative damage in liver and brain of rats[J]. Life Sciences, 2009, 84(3-4):75-80.
[20] Li S, Ding Y, Niu Q, et al.Lutein Has a Protective Effect on Hepatotoxicity Induced by Arsenic via Nrf2 Signaling[J]. Biomed Res Int, 2015(2015):315-205.
[21] Vineetha RC, Archana V, Binu P, et al.L-Ascorbic Acid and α-Tocopherol Reduces Hepatotoxicity Associated with Arsenic Trioxide Chemotherapy by Modulating Nrf2 and Bcl2 Transcr- iption Factors in Chang liver Cells[J]. Nutr Cancer, 2018,70(4): 684-696.
[22] Diaz Z, Laurenzana A, Mann KK, et al.Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity[J]. Leukemia (Basingstoke), 2007, 21(10):2117-2127.
[23] Corsini E, Asti L, Viviani B, et al.Sodium Arsenate Induces Overproduction of Interleukin-1 in Murine Keratinocytes: Role of Mitochondria[J]. Journal of Investigative Dermatology, 1999, 113(5):760-765.
[24] Jomova K, Jenisova Z, Feszterova M, et al.Arsenic: toxicity, oxidative stress and human disease[J]. Journal of Applied Toxicology, 2015, 31(2):95-107.
[25] Yang D, Lv Z, Zhang H, et al.Activation of the Nrf2 Signaling Pathway Involving KLF9 Plays a Critical Role in Allicin Resisting Against Arsenic Trioxide-Induced Hepatotoxicity in Rats[J]. Biological Trace Element Research, 2017, 176(1):192-200.
[26] Wang XJ, Zheng S, Chen W, et al.Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity[J]. Toxicology & Applied Pharmacology, 2007, 225(2): 206-213.
[27] Meng D, Wang X, Chang Q, et al.Arsenic promotes angiogenesis in vitro via a heme oxygenase-1-dependent mechanism[J]. Toxicology & Applied Pharmacology, 2010, 244(3):291-299.
[28] Abiko Y, Shinkai Y, Sumi D, et al.Reduction of arsenic-induced cytotoxicity through Nrf2/HO-1 signaling in HepG2 cells[J]. The Journal of Toxicological Sciences, 2010, 35(3):419-423.
[29] Paul MK, Kumar R, Mukhopadhyay AK .Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells[J]. Toxicology & Applied Pharmacology, 2008, 226(2):140-152.
[30] Mehmet H.Caspases find a new place to hide[J]. Nature, 2000, 403(6765):29-30.
[31] Liu J, Zhao H, Wang Y, et al.Alterations of antioxidant indexes and inflammatory cytokine expression aggravated hepatocellular apoptosis through mitochondrial and death receptor-dependent pathways in Gallus gallus exposed to arsenic and copper[J]. Environmental Science and Pollution Research, 2018, 25(16): 15462-15473.
[32] Wawryk-Gawda E, Patrycja Chylińska-Wrzos, Lis-Sochocka M, et al.P53 protein in proliferation, repair and apoptosis of cells[J]. Protoplasma, 2014, 251(3):525-533.
[33] Lu J, Yu K, Fan S, et al.Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide[J]. Toxicol Appl Pharmacol, 2019, 379: 114687.
[34] Singh AP, Goel RK, Kaur T.Mechanisms Pertaining to Arsenic Toxicity[J]. Toxicology International, 2011, 18(2):87-93.
[35] EI Taghdouini A, van Grunsven LA. Epigenetic regulation of hepatic stellate cell activation and liver fibrosis[J]. Expert Rev Gastroenterol Hepatol, 2016,10(12): 1397-1408.
[36] Wang Z, Tao Y, Qiu T, et al.Taurine protected As2O3-induced the activation of hepatic stellate ells through inhibiting PPAR- alpha-autophagy pathway[J]. Chem Biol Interact, 2019,300: 123-130.
[37] Zhang Y, Wei Z, Liu W, et al.Melatonin protects against arsenic trioxide-induced liver injury by the upregulation of Nrf2 expression through the activation of PI3K/AKT pathway[J]. Oncotarget, 2017, 8(3): 3773-3780.
[38] Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, et al.Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?[J]. British Journal of Haematology, 2001, 112(3):783-786.
[39] Singh S, Rana SV.Ascorbic acid improves mitochondrial function in liver of arsenic-treated rat[J]. Toxicol Ind Health, 2010,26(5): 265-272.
[40] Rana SVS .Protective effect of ascorbic acid against oxidative stress induced by inorganic arsenic in liver and kidney of rat[J]. Indian Journal of Experimental Biology, 2007, 45(4):371-375.
[41] Mondal R, Biswas S, Chatterjee A, et al.Protection against arsenic-induced hematological and hepatic anomalies by supplementation of vitamin C and vitamin E in adult male rats[J]. Journal of Basic and Clinical Physiology and Pharmacology, 2016, 27(6): 643-652.
[42] Xie G, Meng X, Wang F, et al.Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2[J]. Oncotarget, 2017, 8(40):68668-68674.
[43] 刘建群, 彭财英, 舒积成,等. 南天竹提取物对三氧化二砷致肝毒性的保护作用[J]. 时珍国医国药, 2015. 26(4): 772-773.
[44] 黄亚男. 防风及其成分对三氧化二砷诱导的毒性和HL-60/ H9c2细胞凋亡的影响[D].中国中医科学院, 2014.
[45] Zhigang Z, Li G, Yanyan C, et al.Resveratrol, a Natural Antioxidant, Has a Protective Effect on Liver Injury Induced by Inorganic Arsenic Exposure[J]. BioMed Research International, 2014, 2014:1-7.
[46] Binu P, Priya N, Abhilash S, et al.Protective Effects of Eugenol against Hepatotoxicity Induced by Arsenic Trioxide: An Antile- ukemic Drug[J]. Iranian Journal of Medical Sciences, 2018, 43(3):305-312.
[47] Li L, Liu Q, Fan L, et al.Protective effects of oxymatrine against arsenic trioxide-induced liver injury[J]. Oncotarget, 2016, 8(8):12792-12799.
[48] Higurashi T, Hosono K, Takahashi H, et al.Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial[J]. Lancet Oncol, 2016,17(4): 475-483.
[49] Ling S, Ling S, Song L, et al.Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway[J]. International Journal of Oncology, 2017, 50(1):297-309.
[50] Ling S, Shan Q, Liu P, et al.Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I[J]. Cell Death and Disease, 2017, 8(11):e3159.